McKesson to Acquire Precision Medicine Group for Approximately $2.25 Billion

1. 1McKesson (MCK) has entered into a definitive agreement to acquire Precision Medicine Group, a clinical research and biopharma commercialization services company, for approximately $2.25 billion.
2. 2Following the closing of the deal, the company will be integrated into McKesson's oncology and multispecialty segment, subject to customary closing conditions including regulatory approvals, with a closing date yet to be disclosed.
3. 3The acquisition aligns with McKesson's strategy of divesting non-core assets while simultaneously investing in oncology and specialty care.

Source Quartz +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →